FDA Approves Drug to Improve Functional Capacity and Symptoms in Adults with Rare Inherited Heart Condition

The U.S. Food and Drug Administration (FDA) approved Myqorzo (aficamten) tablets to treat adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) to improve functional capacity and symptoms.